Alnylam Pharmaceuticals, Inc. (ALNY) has a MoatMap StockRank of 20/100 based on Quality (68/100), Value (9/100), and Momentum (33/100) factor scores. The current signal is SELL. Alnylam Pharmaceuticals, a US-based healthcare company, does not align with any strong, unpriced macro tailwind from the provided list that would create an asymmetric risk-reward.